genetic testing market is rapidly expanding as healthcare shifts towards personalized and preventive medicine. With enhanced detection technologies, testing now spans a range of applications—from hereditary disease screening and cancer diagnostics to pharmacogenomic insights and ancestry analysis. Key trends include better accessibility, affordable pricing, and consumer-friendly at-home kits, making genetic testing more mainstream than ever.

According to Fortune Business Insights, the genetic testing market was valued at USD 33.82 billion in 2024. The market is projected to grow from USD 37.32 billion in 2025 to USD 76.09 billion by 2032, exhibiting a CAGR of 10.7% during the forecast period. In 2024, North America dominated the genetic testing market with a market share of 41.72%.

Top Companies in the Market

• Hoffmann-La Roche Ltd. (Switzerland)
• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Oxford Nanopore Technologies plc. (U.K.)
• Laboratory Corporation of America Holdings (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Myriad Genetics, Inc. (U.S.)
• QIAGEN (Germany)
• Quest Diagnostics Incorporated (U.S.)
• Danaher Corporation (U.S.)

Key Industry Development

In May 2023, Laboratory Corporation of America (LabCorp) expanded its specialty lab testing capabilities through a strategic agreement with Jefferson Health. This collaboration enhances advanced genetic testing accessibility, supporting more robust diagnostic and personalized treatment services.

Market Drivers & Restraints

Market Drivers: